Impact of Type 2 Diabetes Mellitus on the Efficacy of Immune Checkpoint Blockade in Patients With Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Clin. Cancer Res 2023 Jul 14;29(14)2714-2724, A Cortellini, A D'Alessio, S Cleary, S Buti, M Bersanelli, P Bordi, G Tonini, B Vincenzi, M Tucci, A Russo, F Pantano, M Russano, LS Stucci, MC Sergi, M Falconi, MA Zarzana, D Santini, F Spagnolo, ET Tanda, F Rastelli, FC Giorgi, F Pergolesi, R Giusti, M Filetti, F Lo Bianco, P Marchetti, A Botticelli, A Gelibter, M Siringo, M Ferrari, R Marconcini, MG Vitale, L Nicolardi, R Chiari, M Ghidini, O Nigro, F Grossi, M De Tursi, P Di Marino, P Queirolo, S Bracarda, S Macrini, A Inno, F Zoratto, E Veltri, C Spoto, MG Vitale, K Cannita, A Gennari, DL Morganstein, D Mallardo, L Nibid, G Sabarese, L Brunetti, G Perrone, PA Ascierto, C Ficorella, DJ PinatoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.